Divi's Laboratories Limited

November 07, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

Trading Symbol: **DIVISLAB**

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on November 07, 2026

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated October 22, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2026, has approved, inter alia, the following items of business:

Financial Results

Approved the unaudited financial results for the quarter and half year ended September 30, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of unaudited standalone financial results for the quarter and half year ended September 30, 2026 and Limited Review Report of the Statutory Auditors thereon.
2. Statement of unaudited consolidated financial results for the quarter and half year ended September 30, 2026 and Limited Review Report of the Statutory Auditors thereon.
3. Press release on financial results.

The Board meeting commenced at 10.30 Hrs and concluded at 11.40 Hrs.

This is for your information and records.

Thanking you,
Yours faithfully,
For Divi's Laboratories Limited

SATISH CHOUDHURY MEKA
Digitally signed by SATISH CHOUDHURY MEKA
Date: 2026.11.07 11:50:49 +05'30'

M. Satish Choudhury
Company Secretary & Compliance Officer

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.
Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854
E-mail : mail@divislabs.com, Website : www.divislabs.com

DIVI'S LABORATORIES LIMITED


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER,2026

(Rs. in Crores)

S. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	**30.09.2026**	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	Revenue from operations	**3647**	2974	2660	**6621**	5017	10388
	Other income	**88**	63	146	**144**	265	506
	Total income	**3735**	3037	2806	**6765**	5282	10894
2	**Expenses**						
	a) Cost of materials consumed	**1803**	1495	907	**3298**	1896	4260
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(630)**	(567)	144	**(1197)**	72	(244)
	d) Employee benefits expense	**428**	397	344	**825**	674	1400
	e) Depreciation and amortisation expense	**142**	132	113	**274**	225	461
	f) Finance costs	**13**	6	8	**19**	11	23
	g) Other expenses	**459**	409	370	**861**	737	1484
	Total expenses	**2215**	1872	1886	**4080**	3615	7384
3	**Profit before exceptional Items and tax (1-2)**	**1520**	1165	920	**2685**	1667	3510
4	Exceptional items-Impact of new labour codes	-	-	-	-	-	74
5	**Profit before tax (3-4)**	**1520**	1165	920	**2685**	1667	3436
6	Tax expense						
	a) Current tax	**370**	290	220	**660**	411	869
	b) Deferred tax	**10**	(16)	4	**(6)**	3	(40)
	Total tax expense	**380**	274	224	**654**	414	829
7	**Profit for the period/year (5-6)**	**1140**	891	696	**2031**	1253	2607
8	**Other comprehensive income:**						
	Items that will not be reclassified to Profit or Loss:						
	(i) Gain/(Loss) on Remeasurement of post-employment benefit obligation	**2**	2	-*	**4**	(1)	8
	(ii) Income tax relating to the above	-*	(1)	-*	**(1)**	-*	(2)
	Total other comprehensive income (i+ii)	**2**	1	-*	**3**	(1)	6
9	**Total comprehensive income for the period/year (7+8)**	**1142**	892	696	**2034**	1252	2613
10	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	**53**	53	53	**53**	53	53
11	Other equity excluding revaluation reserve						16658
12	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	**42.97**	33.55	26.24	**76.52**	47.19	98.19
	b) Diluted (Rs.)	**42.97**	33.55	26.24	**76.52**	47.19	98.19

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the company.





DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER,2026

(Rs. in Crores)

S. No.	Particulars	As at	
		30.09.2026 (Unaudited)	31.03.2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	Property, plant and equipment	**7451**	6514
	Capital work-in-progress	**1638**	2113
	Intangible assets	**15**	6
	Financial assets		
	a) Investments	**78**	76
	b) Other financial assets	**72**	67
	Income tax assets (net)	**-**	1
	Other non-current assets	**257**	143
	Sub-total: Non-current assets	**9511**	8920
2	**Current assets**		
	Inventories	**5325**	3711
	Financial assets		
	a) Trade receivables	**3705**	3228
	b) Cash and cash equivalents	**248**	85
	c) Bank balances other than (b) above	**1933**	3286
	d) Other financial assets	**6**	8
	Income-tax assets (net)	**-**	14
	Other current assets	**1150**	702
	Sub-total: Current assets	**12367**	11034
	TOTAL ASSETS	**21878**	19954
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	Equity Share Capital	**53**	53
	Other Equity	**17895**	16658
	Sub-total: Total Equity	**17948**	16711
2	**Liabilities**		
	Non-current liabilities		
	Financial liabilities		
	a) Other financial liabilities	**477**	456
	Provisions	**83**	81
	Deferred tax liabilities (net)	**464**	469
	Other non-current liabilities	**233**	218
	Sub-total: Non-current liabilities	**1257**	1224
3	**Current liabilities**		
	Financial liabilities		
	a) Borrowings	**-**	-
	b) Trade payables		
	Total outstanding dues of micro and small enterprises	**71**	62
	Total outstanding dues other than above	**1658**	1128
	c) Other financial liabilities	**396**	460
	Provisions	**64**	60
	Current tax liabilities (net)	**81**	11
	Other current liabilities	**403**	298
	Sub-total: Current liabilities	**2673**	2019
	Total Liabilities	**3930**	3243
	TOTAL EQUITY AND LIABILITIES	**21878**	19954

Price Waterhouse Chartered Accountants LLP LLPIN AAC-5001 FRN 012754N/N500016 Hyderabad

DIVI'S LABORATORIES LTD. BACKDOWN

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
A. Cash flow from operating activities			
Profit before tax	**2685**	1667	3436
Adjustments for:			
Depreciation and amortisation expense	**274**	225	461
Unrealised foreign exchange (gain)/ loss	**88**	(44)	(106)
Interest income from financial assets at amortised cost	**(115)**	(157)	(284)
Change in fair value of investment in optionally convertible debentures	**(2)**	(2)	(4)
Interest expense	**19**	5	23
Provision for doubtful debts/(written back) including bad debts written off/ (recovered)	**-***	2	1
Loss/(gain) on disposal / discard of property, plant and equipment and intangible assets	**4**	-*	-*
Amortisation of government grants	**-***	-*	-*
	2953	1696	3527
Change in operating assets and liabilities			
(Increase) /Decrease in trade receivables	**(578)**	150	(261)
(Increase) /Decrease in inventories	**(1614)**	(207)	(678)
(Increase) /Decrease in other financial assets	**(3)**	5	3
(Increase) /Decrease in other assets	**(436)**	(137)	(334)
Increase /(Decrease) in employee benefit obligation	**10**	6	95
Increase /(Decrease) in trade payables	**552**	147	303
Increase/ (Decrease) in other financial liabilities	**(58)**	260	478
Increase /(Decrease) in other liabilities	**120**	88	440
Cash generated from operations	**946**	2008	3573
Income taxes paid including withholding tax and net of refunds	**(576)**	(368)	(862)
Net cash inflow from operating activities	**370**	1640	2711
B. Cash flow from investing activities			
Payments for property, plant and equipment	**(871)**	(1544)	(2519)
Proceeds from sale of property, plant and equipment	**-**	3	3
Interest received	**115**	158	284
Proceeds from withdrawal of deposits	**3776**	2855	6156
Investment in deposits	**(2423)**	(2733)	(6142)
Net cash inflow/(outflow) from investing activities	**597**	(1261)	(2218)
C. Cash flow from financing activities			
Proceeds /(repayment) of working capital loans (net)	**-**	83	-
Interest paid	**(7)**	(5)	(5)
Dividend paid to company's shareholders	**(797)**	(796)	(797)
Net cash outflow from financing activities	**(804)**	(718)	(802)

Price Waterhouse Chartered Accountants LLP LLPIN AAC-5001 FRN 012754N/N500016 Hyderabad

DIVI'S LABORATORIES LTD. INVESTIGATOR GUNTUR

STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**163**	(339)	(309)
Cash and cash equivalents at the beginning of the period/year	**85**	394	394
Cash and cash equivalents at end of the period/year	**248**	55	85
Reconciliation of cash and cash equivalents at the end of the period/ year			
Cash and cash equivalents as per Balance sheet	**248**	61	85
Overdraft facilities from bank	**-**	(6)	-
Balance as per Statement of cash flows	**248**	55	85

* Amount is below the rounding off norms adopted by the company.

Notes:

1. The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2026, Statement of Standalone Unaudited Assets and Liabilities as at 30th September, 2026 and Statement of Standalone Unaudited Cash Flows for the half year ended 30th September, 2026 ('Standalone Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Standalone Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2026. The statutory auditors have carried out a limited review of this Standalone Statement and issued an unmodified report thereon.
2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
3. The Company does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
4. Details of Forex gain /(loss) are as given below:

(Rs. in Crores)

	Quarter ended			Half Year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	**30.09.2026**	30.09.2025	31.03.2026
Forex gain/(loss)	**27**	(7)	64	**20**	103	210

Forex gain has been included in Other Income and loss has been included in Other Expenses.

For Divi's Laboratories Limited

Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer

Place: Hyderabad
Date: November 07, 2026

Price Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended September 30, 2026 and the year to date results for the period April 01, 2026 to September 30, 2026, the Statement of Assets and Liabilities as on that date and the Statement of Cash Flows for the half-year ended on that date which are included in the accompanying Statement of Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026, the Statement of Standalone Unaudited Assets and Liabilities as at September 30, 2026 and the Statement of Standalone Unaudited Cash Flows for the half year ended September 30, 2026 (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review.

2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196SEKAVP3698

Place of the Signature: Hyderabad
Date: November 7, 2026

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER,2026

(Rs. in Crores)

S. No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	**30.09.2026**	**30.09.2025**	31.03.2026
		Unaudited	Unaudited	Unaudited	**Unaudited**	Unaudited	Audited
1	**Income**						
	Revenue from operations	**3676**	3080	2715	**6756**	5125	10560
	Other income	**94**	64	145	**151**	264	507
	Total income	**3770**	3144	2860	**6907**	5389	11067
2	**Expenses**						
	a) Cost of materials consumed	**1812**	1503	937	**3315**	1947	4378
	b) Purchases of stock-in-trade	**-**	-	-	**-**	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(631)**	(517)	136	**(1148)**	82	(285)
	d) Employee benefits expense	**444**	408	354	**852**	694	1442
	e) Depreciation and amortisation expense	**142**	133	113	**275**	225	463
	f) Finance costs	**13**	6	8	**19**	11	23
	g) Other expenses	**485**	431	400	**909**	785	1584
	Total expenses	**2265**	1964	1948	**4222**	3744	7605
3	**Profit before exceptional items and tax (1-2)**	**1505**	1180	912	**2685**	1645	3462
4	Exceptional items-Impact of new labour codes	**-**	-	-	**-**	-	74
5	**Profit before tax (3-4)**	**1505**	1180	912	**2685**	1645	3388
6	Tax expense						
	a) Current tax	**371**	291	220	**662**	411	868
	b) Deferred tax	**7**	(13)	3	**(6)**	-*	(48)
	Total tax expense	**378**	278	223	**656**	411	820
7	**Profit for the period/year (5-6)**	**1127**	902	689	**2029**	1234	2568
8	Profit for the period/year attributable to:						
	Owners of Holding Company	**1127**	902	689	**2029**	1234	2568
	Non-Controlling Interest	**-**	-	-	**-**	-	-
9	**Other Comprehensive Income:**						
	a) Items that will not be reclassified to profit or loss:						
	i) Gain/(loss) on Remeasurement of post-employment benefit obligations	**2**	2	-*	**4**	(1)	8
	ii) Income tax relating to the above	**-***	(1)	-*	**(1)**	-*	(2)
	b) Items that will be reclassified to profit or loss:						
	i) Gain on exchange differences in translating the financial statements of foreign operations	**-***	1	5	**1**	9	20
	ii) Income tax relating to the above	**-***	-*	(2)	**-***	(2)	(5)
	Total other comprehensive income (a+b)	**2**	2	3	**4**	6	21
10	Total other comprehensive income for the period/ year attributable to:						
	Owners of Holding Company	**2**	2	3	**4**	6	21
	Non-Controlling Interest	**-**	-	-	**-**	-	-
11	**Total comprehensive income for the period/year (7+9)**	**1129**	904	692	**2033**	1240	2589
12	Total comprehensive income for the period/ year attributable to:						
	Owners of Holding Company	**1129**	904	692	**2033**	1240	2589
	Non-Controlling Interest	**-**	-	-	**-**	-	-
13	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	**53**	53	53	**53**	53	53
14	Other equity excluding revaluation reserve						16708
15	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	**42.49**	33.95	25.97	**76.44**	46.46	96.75
	b) Diluted (Rs.)	**42.49**	33.95	25.97	**7644**	46.46	96.75

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the group.

Price Waterhouse Chartered Accountants LLP LLPIN AAC-5001 FRN 012754N/N500016 Hyderabad

DIVI'S LABORATORIES LTD. HYDERABAD

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER,2026

(Rs. in Crores)

	Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
A	**ASSETS**		
1	**Non-current assets**		
	Property, plant and equipment	**7452**	6515
	Right of use assets	**6**	7
	Capital work-in-progress	**1638**	2113
	Intangible assets	**15**	6
	Financial assets		
	a) Investments	**71**	69
	b) Other financial assets	**73**	67
	Income tax assets (net)	**-***	3
	Deferred tax asset	**13**	14
	Other non-current assets	**257**	143
	Sub-total: Non-current assets	**9525**	8937
2	**Current assets**		
	Inventories	**5540**	3954
	Financial assets		
	a) Trade receivables	**3487**	2984
	b) Cash and cash equivalents	**303**	128
	c) Bank balances other than (b) above	**1933**	3286
	d) Other financial assets	**6**	8
	Income tax assets (net)	**-**	15
	Other current assets	**1170**	721
	Sub-total: Current assets	**12439**	11096
	TOTAL ASSETS	**21964**	20033
B	**EQUITY AND LIABILITIES**		
1	**Equity:**		
	Equity Share Capital	**53**	53
	Other Equity	**17944**	16708
	Sub-total: Total equity	**17997**	16761
2	**Liabilities:**		
	Non-current liabilities		
	Financial liabilities		
	a) Other financial liabilities	**477**	456
	b) Lease liabilities	**4**	5
	Provisions	**83**	81
	Deferred tax liabilities (net)	**463**	469
	Other non-current liabilities	**233**	218
	Sub-total: Non-current liabilities	**1260**	1229
3	**Current Liabilities**		
	Financial liabilities		
	a) Borrowings	**-**	-
	b) Lease liabilities	**2**	2
	c) Trade payables:		
	Total outstanding dues of micro and small enterprises	**71**	62
	Total outstanding dues other than above	**1688**	1149
	d) Other financial liabilities	**397**	460
	Provisions	**64**	60
	Current tax liabilities (net)	**81**	12
	Other current liabilities	**404**	298
	Sub-total: Current liabilities	**2707**	2043
	Total Liabilities	**3967**	3272
	TOTAL EQUITY AND LIABILITIES	**21964**	20033

* Amount is below the rounding off norms adopted by the group.

Price Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
A. Cash flow from operating activities			
Profit before tax	**2685**	1645	3388
Adjustments for:			
Depreciation and amortisation expense	**275**	225	463
Unrealised foreign exchange (gain)/ loss	**88**	(40)	(86)
Interest income from financial assets at amortised cost	**(115)**	(157)	(284)
Change in fair value of investment in optionally convertible debentures	**(2)**	(2)	(4)
Interest expense	**19**	5	23
Provision for doubtful debts/(written back) including bad debts written off/(recovered)	**(1)**	1	1
Loss/(gain) on disposal /discard of property, plant and equipment and intangible assets	**4**	-*	-*
Amortisation of government grants	**-***	-*	-*
	2953	1677	3501
Change in operating assets and liabilities			
(Increase) /Decrease in trade receivables	**(604)**	188	(141)
(Increase) /Decrease in inventories	**(1585)**	(197)	(718)
(Increase) /Decrease in other financial assets	**(4)**	5	2
(Increase) /Decrease in other assets	**(449)**	(143)	(350)
Increase /(Decrease) in employee benefit obligation	**10**	7	95
Increase /(Decrease) in trade payables	**561**	124	294
Increase / (Decrease) in other financial liabilities	**(43)**	260	478
Increase /(Decrease) in other liabilities	**120**	91	439
Cash generated from operations	**959**	2012	3600
Income taxes paid including withholding tax and net of refunds	**(575)**	(367)	(862)
Net cash inflow from operating activities	**384**	1645	2738
B. Cash flow from investing activities			
Payments for property, plant and equipment	**(872)**	(1544)	(2520)
Proceeds from sale of property, plant and equipment	**-**	3	3
Interest received	**115**	158	284
Proceeds from withdrawal of deposits	**3776**	2855	6156
Investment in deposits	**(2423)**	(2733)	(6142)
Net cash inflow/(outflow) from investing activities	**596**	(1261)	(2219)
C. Cash flow from financing activities			
Principal element of lease liabilities	**(1)**	(2)	(2)
Proceeds /(repayment) of working capital loans (net)	**-**	83	-
Interest paid	**(7)**	(5)	(5)
Dividend paid to company's shareholders	**(797)**	(796)	(797)
Net cash outflow from financing activities	**(805)**	(720)	(804)

Price Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

DIVI'S LABORATORIES LTD. GACHIBOWLI

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**175**	(336)	(285)
Cash and cash equivalents at the beginning of the period/year	**128**	413	413
Cash and cash equivalents at end of the period/year	**303**	77	128
Reconciliation of cash and cash equivalents at the end of the period/ year			
Cash and cash equivalents as per Balance sheet	**303**	83	128
Overdraft facilities from bank	**-**	(6)	-
Balance as per Statement of cash flows	**303**	77	128

* Amount is below the rounding off norms adopted by the group.

Notes:

1. The above Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2026, Statement of Consolidated Unaudited Assets and Liabilities as at 30th September, 2026 and Statement of Consolidated Unaudited Cash Flows for the half year ended 30th September, 2026 ('Consolidated Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2026. The statutory auditors have carried out a limited review of this Consolidated Statement and issued an unmodified report thereon.
2. The Consolidated Unaudited Financial Results include the financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group")
3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108.
4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
5. Details of Forex gain /(loss) are as given below:

(Rs. in Crores)

	Quarter ended			Half Year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	**30.09.2026**	30.09.2025	31.03.2026
Forex gain/(loss)	**24**	(7)	63	**17**	102	211

Forex gain has been included in Other Income and loss has been included in Other Expenses.

For Divi's Laboratories Limited

Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer

Place: Hyderabad
Date: November 07, 2026

Price Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries hereinafter referred to as the "Group"), (refer Note 2 on the Consolidated Statement) for the quarter ended September 30, 2026 and the year to date results for the period April 01, 2026 to September 30, the Consolidated Unaudited Statement of Assets and Liabilities as on that date and the Consolidated Unaudited Statement of Cash Flows for the half-year ended on that date which are included in the accompanying Statement of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026, the Statement of Consolidated Unaudited Assets and Liabilities as at September 30, 2026 and the Statement of Consolidated Unaudited Cash Flows for the half year ended September 30, 2026 (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.

2. This Consolidated Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.

3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Consolidated Statement includes the results of the following entities:

   a) Divis Laboratories (USA) Inc.
   b) Divi's Laboratories Europe AG

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196RBALFB7349

Place of the Signature: Hyderabad
Date: November 7, 2026

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854
Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED 7th November 2026

Divi's Laboratories earns a Consolidated Total Income of ₹ 3770 crores for Q2 of FY27

Consolidated Financial Results

For the quarter ended 30th September 2026

Divi's Laboratories has earned a consolidated total income ₹ 3770 crores for the quarter ended 30th September 2026 as against a consolidated total income of ₹ 2860 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to ₹ 1505 crores as against a PBT of ₹ 912 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to ₹ 1127 crores as against a PAT of ₹ 689 crores for the corresponding quarter of the previous year. For the current quarter, we have forex gain of ₹ 24 crores as against a gain of ₹ 63 crores during the corresponding quarter of the previous year.

For the half year ended 30th September 2026

For the half year ended 30th September 2026 the Company has earned a consolidated total income of ₹ 6907 crores as against a consolidated total income of ₹ 5389 crores during the corresponding half-year of the previous year. PBT for the current half year came to ₹ 2685 crores as against ₹ 1645 crores for the corresponding half year of the previous year. PAT for the current half year came to ₹ 2029 crores as against ₹ 1234 crores for the corresponding half year of the previous year. For the current half-year, we had a forex gain of ₹ 17 crores against a gain of ₹ 102 crores for the corresponding half year of the previous year.

Standalone Financial Results

On a standalone basis, the Company's earnings are given below: ₹ in crores

Particulars	For the quarter ended		For the half year ended	
	30-09-2026	30-09-2025	30-09-2026	30-09-2025
Total Income	3735	2806	6765	5282
PBT	1520	920	2685	1667
Tax Expense	380	224	654	414
PAT	1140	696	2031	1253

Forex Gain / (Loss):
Particulars of forex gain for the period, on standalone basis, are given below: ₹ in crores

Particulars	For the quarter ended		For the half year ended	
	30-09-2026	30-09-2025	30-09-2026	30-09-2025
Forex gain	27	64	20	103

DIVI'S LABORATORIES LTD. HYDERABAD-32 GACHIBOWLI